Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Insmed reported $-44653000 in Equity Capital and Reserves for its fiscal quarter ending in March of 2023.

Equity Capital And Reserves Change
Alimera Sciences ALIM:US USD -18916000 1.89M
BioMarin Pharmaceutical BMRN:US USD 4.66B 55.89M
Cytokinetics CYTK:US USD -229020000 121.12M
DBV Technologies DBVT:US USD 179.09M 15.36M
Dynavax Technologies DVAX:US USD 563.73M 17.28M
Gilead Sciences GILD:US USD 20.94B 270M
Heron Therapeutics HRTX:US USD -11429000 25M
Insmed INSM:US USD -44653000 132.6M
Iveric bio Inc. OPHT:US USD 477.05M 57.61M
Mirati Therapeutics MRTX:US USD 862.63M 133.89M
Novartis NVS:US USD 52.06B 7.28B
Regeneron Pharmaceuticals REGN:US USD 23.5B 831.2M
Sarepta Therapeutics SRPT:US USD 712.75M 327.8M
Seattle Genetics SGEN:US USD 2.72B 80.66M
Ultragenyx Pharmaceutical RARE:US USD 220.48M 132.01M
Vertex Pharmaceuticals VRTX:US USD 14.43B 519.6M